Search | Clinical Trials Finder

Conditions: Opioid-use Disorder
Interventions: reSET-O app; Device
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Harrisburg, Pennsylvania

Conditions: Metastatic Breast Cancer
Interventions: Erdafitinib, Palbociclib, Fulvestrant; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 6
States / cities: Birmingham, Alabama • New York, New York • Pittsburgh, Pennsylvania + 3 more

Conditions: Human Immuno-deficiency Virus (HIV) Disease
Interventions: Budigalimab, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 43
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more

Conditions: Open Fracture
Interventions: Vancomycin; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 89 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Colonic Neoplasms, Colorectal Neoplasms
Interventions: GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Adjuvant chemotherapy; Drug
Lead sponsor: Gritstone bio, Inc.; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Detroit, Michigan • New York, New York • Cincinnati, Ohio

Conditions: Dental Anesthesia, Anesthesia, Local, Anesthesia, Reversal
Interventions: OraVerse, Sham injection; Drug · Other
Lead sponsor: Novocol Pharmaceutical of Canada, Inc.; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: San Francisco, California • Indianapolis, Indiana • Columbus, Ohio + 4 more

Conditions: Myelodysplastic Syndrome
Interventions: eltrombopag olamine, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 24
States / cities: Birmingham, Alabama • Santa Monica, California • Stanford, California + 20 more

Conditions: Rib Fractures
Interventions: ESP block with catheter using ropivacaine (bolus followed by continuous infusion), Lidocaine bolus (1 mg/kg) and infusion starting at 1 mg/kg/h; Procedure · Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 55 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Non-interventional study.; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 47
States / cities: Highlands Ranch, Colorado • Wheat Ridge, Colorado • Clearwater, Florida + 43 more

Conditions: Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, High Risk Chronic Myelomonocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory High Risk Myelodysplastic Syndrome
Interventions: Liposome-encapsulated Daunorubicin-Cytarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumor, Adult
Interventions: HL-085; Drug
Lead sponsor: Shanghai Kechow Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Austin, Texas • San Antonio, Texas

Conditions: Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
Interventions: Neoantigen specific TCR-T cell drug product; Biological
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Promyelocytic Leukemia
Interventions: All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), Idarubicin, Gemtuzumab Ozogamicin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Nonmelanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma
Interventions: Vitamin D (VitD), Placebo, Photodynamic therapy (PDT), Mohs surgery or electrodessication & curettage (ED&C) (standard of care); Dietary Supplement · Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetic Foot Ulcer
Interventions: Standard of Care, NeoThelium FT; Other
Lead sponsor: NuScience Medical Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Alexandria, Louisiana • Franklinton, Louisiana • Hammond, Louisiana + 5 more

Conditions: Breast Cancer
Interventions: Standard Therapy, Local Therapy; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Intensity-Modulated Radiation Therapy (IMRT), Docetaxel+IMRT; Radiation · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2023
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Drug Addiction
Interventions: Pairing condition; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 35 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dental Extraction
Interventions: fentanyl and Remimazolam; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Aorta Aneurysm, Dissection of Aorta
Interventions: Clevidipine; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 21
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more

Conditions: Ischemic Stroke, Chronic Stroke, Hemiparesis, Arm Paralysis
Interventions: CTX0E03 Drug Product and delivery device, Placebo; Combination Product · Drug
Lead sponsor: ReNeuron Limited; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 23
States / cities: Little Rock, Arkansas • Irvine, California • Los Angeles, California + 19 more

Conditions: Malignant Melanoma
Interventions: Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2031
U.S. locations: 3
States / cities: San Diego, California • Memphis, Tennessee • Houston, Texas

Conditions: Respiratory Failure
Interventions: Cuff Leak Test, Dexamethasone 4mg; Diagnostic Test · Drug
Lead sponsor: St. Joseph's Healthcare Hamilton; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

reSET-O RCT (Randomized Controlled Trial)

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

Placement of Antibiotic Powder in Wounds During the Emergency Room

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Analgesic Techniques for Rib Fractures

Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Phase I Study of HL-085 in Patients With Advanced Solid Tumors

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)

Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer

Drug Effects on Preference and Reward

Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction

Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection

Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection

Investigation of Neural Stem Cells in Ischemic Stroke

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU Patients